71 related articles for article (PubMed ID: 1602373)
1. Platelet-activating factor reduces spinal cord blood flow and causes behavioral deficits after intrathecal administration in rats through a specific receptor mechanism.
Faden AI; Halt P
J Pharmacol Exp Ther; 1992 Jun; 261(3):1064-70. PubMed ID: 1602373
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH
J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
[TBL] [Abstract][Full Text] [Related]
3. Rat liver blood flow after ischemia and reperfusion. The effects of the platelet-activating factor antagonist WEB-2170 and of removing circulating leukocytes.
Chávez-Cartaya RE; Metcalfe S; Ramirez-Romero P; Calne R; Jamieson NV
Transplantation; 1994 May; 57(10):1440-4. PubMed ID: 8197604
[TBL] [Abstract][Full Text] [Related]
4. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular responses to exogenous platelet-activating factor (PAF) in anesthetized ponies, and the effects of a PAF antagonist, WEB 2086.
Wilson DV; Eberhart SW; Robinson NE; Rice R; Gray PR
Am J Vet Res; 1993 Feb; 54(2):274-9. PubMed ID: 8430938
[TBL] [Abstract][Full Text] [Related]
6. Arginine8-vasopressin reduces spinal cord blood flow after spinal subarachnoid injection in rats.
Long JB; Martinez-Arizala A; Johnson SH; Holaday JW
J Pharmacol Exp Ther; 1989 May; 249(2):499-506. PubMed ID: 2524587
[TBL] [Abstract][Full Text] [Related]
7. Platelet-activating factor and WEB-2086 directly modulate rat cardiomyocyte contractility.
Delbridge LM; Stewart AG; Goulter CM; Morgan TO; Harris PJ
J Mol Cell Cardiol; 1994 Feb; 26(2):185-93. PubMed ID: 8006979
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist.
Tsunoda H; Sakuma Y; Harada K; Muramoto K; Katayama S; Horie T; Shimomura N; Clark R; Miyazawa S; Okano K
Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331
[TBL] [Abstract][Full Text] [Related]
10. Effect of systemic platelet-activating factor (PAF) on the rabbit spinal cord microcirculation.
Lindsberg PJ; Jacobs TP; Paakkari IA; Hallenbeck JM; Feuerstein G
J Lipid Mediat; 1990; 2(1):41-58. PubMed ID: 2133267
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist. Effects on microvascular permeability, hypotension and nephrosis.
Sakuma Y; Shirato M; Nagaoka J; Obaishi H; Tsunoda H; Katayama S; Ono H; Katayama K
Arzneimittelforschung; 1991 Dec; 41(12):1255-9. PubMed ID: 1815526
[TBL] [Abstract][Full Text] [Related]
12. Platelet-activating factor (PAF) receptor-mediated calcium mobilization and phosphoinositide turnover in neurohybrid NG108-15 cells: studies with BN50739, a new PAF antagonist.
Yue TL; Gleason MM; Gu JL; Lysko PG; Hallenbeck J; Feuerstein G
J Pharmacol Exp Ther; 1991 Apr; 257(1):374-81. PubMed ID: 1850473
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man.
Brecht HM; Adamus WS; Heuer HO; Birke FW; Kempe ER
Arzneimittelforschung; 1991 Jan; 41(1):51-9. PubMed ID: 1646613
[TBL] [Abstract][Full Text] [Related]
14. Involvement of platelet activating factor in immediate heart response to lipopolysaccharide.
Jakubowski A; Olszanecki R; Chlopicki S
J Physiol Pharmacol; 2004 Jun; 55(2):409-21. PubMed ID: 15213362
[TBL] [Abstract][Full Text] [Related]
15. Platelet-activating factor receptor antagonist improves renal function and glomerular lesions in renal ablation.
Thaiss F; Mihatsch MJ; Oberle G; Haberstroh U; Brecht HM; Stahl RA
J Lab Clin Med; 1994 Dec; 124(6):775-81. PubMed ID: 7798789
[TBL] [Abstract][Full Text] [Related]
16. Inhibitor effect of apafant on bronchopulmonary responses to platelet activating factor and to antigen in rats.
Akagi M; Nishioka E; Kanoh R; Tachibana M; Fukuishi N
Arzneimittelforschung; 1997 Dec; 47(12):1364-9. PubMed ID: 9450165
[TBL] [Abstract][Full Text] [Related]
17. Opiate-receptor antagonist nalmefene improves neurological recovery after traumatic spinal cord injury in rats through a central mechanism.
Faden AI; Sacksen I; Noble LJ
J Pharmacol Exp Ther; 1988 May; 245(2):742-8. PubMed ID: 3367315
[TBL] [Abstract][Full Text] [Related]
18. Platelet-activating factor mediates pulmonary macromolecular leak following intestinal ischemia-reperfusion.
Carter MB; Wilson MA; Wead WB; Garrison RN
J Surg Res; 1996 Feb; 60(2):403-8. PubMed ID: 8598677
[TBL] [Abstract][Full Text] [Related]
19. Prevention of platelet-activating factor-induced gastrointestinal lesions in rats by the new specific antagonist N-(2-dimethylaminoethyl)-N-(3-pyridinylmethyl)[4-(2,4,6-triisopropylphe nyl) thiazol-2yl]amine.
Giudice A; Herbert JM; Maffrand JP; Manara L; Manzoni L; Le Fur G
Arzneimittelforschung; 1996 Apr; 46(4):407-12. PubMed ID: 8740089
[TBL] [Abstract][Full Text] [Related]
20. Platelet activating factor impairs pressor responses to noradrenaline in the anaesthetized rat but does not mediate endotoxin-induced hyporeactivity.
Bouvier C; Guc MO; Furman BL; Parratt JR
Circ Shock; 1994 Jan; 42(1):14-9. PubMed ID: 8149505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
